EPHX2 and hypertensive disorder: In another study on a murine model of hypertension treated with angiotensin (Ang)-II, co-administration of sEH inhibitor with EPA and DHA effectively decreased Ang-II-dependent hypertension and attenuated release of renal inflammatory markers, such as MCP-1 and prostaglandins [226].